Prices from Twelve Data (may be delayed). Hong Kong Stock Exchange tickers (e.g. “0700.HK”) instead use EODHD, the only free source found that covers HKEX. Fundamentals from SEC EDGAR (US filers only). Insider transactions, institutional holdings, sentiment-scored news, and the next earnings date (US tickers only, not covered for HKEX) are from Alpha Vantage. Not investment advice. See the data sources appendix on each company page for full detail.
← Back to search

Shell plc American Depositary Shares (Each representing two Ordinary shares) SHEL

NYSE

$93.76

-0.78 (-0.83%)

$93.7609-21

A quick, factual read on the price trend and the underlying business, not a recommendation, and not a substitute for reading the numbers below yourself.

At a glance

Above 200DMANeutral momentumNear 52-week highModerate ROEUnavailableLower than marketUnavailable

73

Technical strength

Trend, momentum, position vs averages

  • Price is 11.3% above its 200-day moving average.
  • 14-day RSI is 57.
  • Sits at 82% of its 52-week range (0% = low, 100% = high).

25

Fundamental quality

Margins, returns, leverage, growth

  • Net margin is 6.2%.
  • Return on equity is 10.2%.
  • Revenue grew -17.0% year over year.

$94.69

Open

$94.54

Previous close

$99.16

52-week high

$68.63

52-week low

230,113

Volume

5,362,020

Avg. volume

$90.95

50-day avg.

+23%

Volatility (ann.)

Context

  • Trading 5.4% below its 52-week high, and closer to the top of its 52-week range.
  • Trading 3.1% above its 50-day average price, consistent with recent upward momentum.
  • Annualized price volatility over this period is about 23%, which is moderately volatile next to a typical broad-market stock (commonly ~15-25%).

About

AstraZeneca plc (AZ) is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Fundamentals & valuation (FY2025, from SEC filings)

Core financials

$316.6bn

Revenue (latest FY)

-16.97%

Revenue growth (YoY)

$19.6bn

Net income (latest FY)

$40.2bn

Cash & equivalents

+6.20%

Net margin

$32.9bn

Working capital

$192.6bn

Shareholders' equity

$54.2bn

Operating cash flow

Valuation multiples

$93.76

Price

Growth & returns

-16.97%

Revenue growth (YoY)

+10.20%

ROE

+5.07%

ROA

Credit metrics & WACC inputs

-0.03

Beta (vs. S&P 500)

$40.2bn

Cash & equivalents

Want to go further?

Build your own investment report from this data. Pick a report type, add your thesis, and export a PDF.